EVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evotec SE is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical analysis shows a bearish trend, the financial performance indicates declining revenue and negative gross margins, and there are no significant positive catalysts or recent news to support a strong upward movement in the near term. While analysts have a buy rating with a higher price target, the lack of immediate trading signals and weak financials suggest holding off on investment for now.
The MACD is negative and expanding downward, indicating bearish momentum. The RSI is neutral at 33.606, but the moving averages (SMA_200 > SMA_20 > SMA_5) confirm a bearish trend. The price is below the pivot level of 3.286, with key support at 3.057 and resistance at 3.516.
Analyst Berenberg initiated a buy rating with a EUR 10 price target, citing the company's leading position in drug discovery and favorable market trends.
The stock has experienced a significant price drop (-4.59% in regular market trading and -3.06% pre-market). Financials show declining revenue (-5.70% YoY) and negative gross margins (-100.40% YoY). There is no recent news or significant insider or hedge fund activity to indicate positive momentum.
In Q3 2025, revenue dropped by 5.70% YoY to 191,553,770.13. Net income improved slightly but remains negative at -50,360,780.86 (up 15.65% YoY). EPS increased to -0.28 (up 12.00% YoY), but gross margin dropped significantly to -0.04 (-100.40% YoY).
Berenberg initiated coverage with a Buy rating and a EUR 10 price target, citing strong market positioning and growth potential. However, no other recent analyst updates directly pertain to Evotec SE.
